The Journal of Pediatrics
Volume 148, Issue 3 , Pages 294-295 , March 2006

Ritonavir and fluticasone: Beware of this potentially fatal combination

  • Albert Martin Li, MB

      Affiliations

    • Corresponding Author InformationReprint requests: Dr Albert M. Li, Chinese University of Hong Kong, Department of Pediatrics, Prince of Wales Hospital, 6/F, Clinical Sciences Building, Shatin, Hong Kong

Received 3 December 2005 ,Accepted 23 December 2005.

References 

  1. UNAIDS/WHO AIDS epidemic update. http://www.unaids.org/epi/2005/. December 2005.
  2. Dybul M , Fauci AS , Bartlett JG , et al.   Panel on Clinical Practices for Treatment of HIV Guidelines for using antiretroviral agents among HIV-infected adults and adolescents . Ann Intern Med . 2002;137:381–433
  3. Zeldin RK , Petruschke RA . Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients . Antimicrob Chemother . 2004;53:4–9
  4. Chrousos PC , Harris AG . Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy . Neuroimmunomodulation . 1998;5:288–308
  5. Lipworth BJ , Jackson CM . Safety of inhaled and intranasal corticosteroids (lessons for the new millennium) . Drug Saf . 2000;1:11–33
  6. Taylor AV , Laoprasert N , Zimmerman D , et al.   Adrenal suppression secondary to inhaled fluticasone propionate . Ann Allergy Asthma Immunol . 1999;83:68–70
  7. Samaras K , Pett S , Gowers A , et al.   Iatrogenic Cushing’s syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors (six cases) . J Clin Endocrinol Metab . 2005;90:4394–4398
  8. Soldatos G , Sztal-Mazer S , Woolley I , et al.   Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction . Intern Med J . 2005;35:67–68
  9. Gillett MJ , Cameron PU , Nguyen HV , et al.   Iatrogenic Cushing’s syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone . AIDS . 2005;19:740–741
  10. Chen F , Kearney T , Robinson S , et al.   Cushing’s syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone . Sex Transm Infect . 1999;75:274
  11. Clevenbergh P , Corcostegui M , Gerard D , et al.   Iatrogenic Cushing’s syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen . J Infect . 2002;44:194–195
  12. Gupta SK , Dube MP . Exogenous Cushing’s syndrome mimicking human immunodeficiency virus lipodystrophy . Clin Infect Dis . 2002;35:E69–E71
  13. Hillebrand-Haverkort ME , Prummel MF , ten Veen JH . Ritonavir-induced Cushing’s syndrome in a patient treated with nasal fluticasone . AIDS . 1999;13:1803
  14. Johnson SR , Marion AA , Vrchoticky T , et al.   Cushing’s syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone . J Pediatr . 2006;148:386–388
  15. Holt S , Suder A , Weatherall M , et al.   Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma (meta-analysis) . BMJ . 2001;323:253–256
  16. Lipworth B . Systemic adverse effects of inhaled corticosteroid therapy (a systematic review and meta-analysis) . Arch Intern Med . 1999;159:941–955
  17. Currie GP , Lee DKC , Srivastava P . Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? . Chest . 2005;128:2954–2962
  18. Hindmarsh P . Exogenous glucocorticoids influence adrenal function, but assessment can be difficult . BMJ . 2002;324:1083
  19. Yiallouros PK , Milner AD , Conway E , et al.   Adrenal function and high dose inhaled corticosteroids for asthma . Arch Dis Child . 1997;76:405–410
  20. Kannisto S , Laatikainen A , Taivainen A , et al.   Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression during inhaled steroid therapy in adult asthmatic patients . Eur J Endocrinol . 2004;150:687–690

 Dr Li received financial support to attend postgraduate meetings from Glaxo SmithKline, which makes inhaled fluticasone.

PII: S0022-3476(05)01243-6

doi: 10.1016/j.jpeds.2005.12.057

The Journal of Pediatrics
Volume 148, Issue 3 , Pages 294-295 , March 2006

Article Tools